Medtronic Will Host a Webcast of Its Diabetes Group Analyst and Investor Briefing
on Monday, June 25 from 9 - 10 a.m. EDT

DUBLIN - June 19, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 78th Scientific Sessions of the American Diabetes Association, in Orlando, June 22-26. A significant portion of the scientific data being presented focuses on Medtronic's insulin pump systems, including the MiniMed(TM) 670G system, the world's first hybrid closed-loop system. Data will also be presented on the Sugar.IQ(TM) app, powered by IBM Watson technology, as well as managing glucose control using the Guardian(TM) Connect continuous glucose monitoring (CGM) system.

Scientific Presentations
Cognitive Science

Continuous Glucose Monitoring (CGM)

Insulin Pump Therapy

Company Exhibit Floor Presentations
Medtronic will be showcasing their newest and most advanced technologies at Booth #639, including the MiniMed 670G system as well as the Guardian Connect continuous glucose monitoring (CGM) system with the Sugar.IQ intelligent diabetes assistant app.

Additionally, Medtronic will host a series of presentations at the booth from Saturday through Monday, providing an opportunity for attendees to learn about the application of Medtronic technologies from experts. A full list of presentations is below:

  • MiniMed 670G System Real World Data & Patient Stories - Saturday, June 23 at 10:30 a.m. and Sunday, June 24 at 1:30 p.m.
  • Digital Therapeutics: Improving Adherence and Outcomes - Saturday, June 23 at 3 p.m.
  • Creating Personalized Treatment Plans Through iPro(TM)2 Professional CGM - Sunday, June 24 at 10:30 a.m.
  • Guardian Connect CGM & Sugar.IQ Insights - Sunday, June 24 at 3 p.m. and Monday, June 25 at 10:30 a.m. and 1:30 p.m.

Finally, Medtronic will also be hosting two Product Theater Presentations. The date and time for each presentation is as follows:

  • "The Guardian Connect System: Utilizing predictive alerts and data backed insights to help with diabetes management" - presented by Dr. Timothy S. Bailey and Huzefa Neemuchwala on Sunday, June 24 at 10:15 a.m.
  • "MiniMed 670G System: Increasing time in range with automated insulin delivery" - presented by Drs. Anders L. Carlson and Jennifer L. Sherr on Monday, June 25 at 10:15 a.m.

Analyst and Investor Briefing
Medtronic will host a webcast to highlight its Diabetes Group on Monday, June 25, from 9 a.m. to 10 a.m. EDT. The webcast will feature remarks from Medtronic management, including comments on Medtronic's clinical data, product pipelines, and market outlooks. The live audio webcast can be accessed by clicking on the Investor Events link at on June 25. Within 24 hours of the webcast, a replay will be available on the same webpage. This event is not part of the official ADA Scientific Sessions.

Sponsored Events
Medtronic is also proud to serve as a sponsor for three events at this year's ADA:

  • Women Interprofessional Networking (WIN) ADA Networking Reception - taking place Friday, June 22 from 6:30 - 8:30 p.m. EDT at the Orange County Convention Center in the Third Level Foyer
  • 12th Annual Diabetes Forum - taking place on Monday, June 25 from 6:30 - 8:30 p.m. at the Rosen Centre Hotel
  • Musings Under the Moon - taking place on Monday, June 25 from 9:30 p.m. - 1:30 a.m. at BB King's Blues Club

About the Diabetes Group at Medtronic (
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


Janet Cho
Public Relations

Ryan Weispfenning
Investor Relations